CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
BI 6727, IV infusiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01023958
NCT01023958Phase 2Completed
CompareCT.gov

An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy

Boehringer Ingelheim·interventional·Posted Dec 2, 2009·Updated Nov 22, 2017

In Brief

A Phase 2 clinical trial evaluating BI 6727, IV infusion for Neoplasms. Completed, enrolled 50 participants across 21 sites in 2 countries.

Detailed Summary

The primary objective of this trial is to evaluate the efficacy and safety of BI 6727 in patients with locally advanced, metastatic or recurrent urothelial cancer after failure of first line or adjuvant/neoadjuvant chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesTaiwan, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2, 2009
Enrollment StartNov 19, 2009
Primary CompletionSep 19, 2011
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.6 years ago

Interventions

BI 6727, IV infusiondrug

phase II